UC-MSCs in combination with eltrombopag, a non-peptide MPL agonist, further activated JAK/STAT and MAPK signaling pathways through MPL and exerted a synergetic effect on enhancing CML cell differentiation. The gene discussed is SOAT1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.